|
UBE2N expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.31383834104327E-13 |
| Normal-vs-Stage2 |
2.20689999608226E-08 |
| Normal-vs-Stage3 |
4.9960036108132E-15 |
| Normal-vs-Stage4 |
1.62592161956354E-12 |
| Stage1-vs-Stage2 |
8.617800E-01 |
| Stage1-vs-Stage3 |
1.420130E-02 |
| Stage1-vs-Stage4 |
1.762030E-03 |
| Stage2-vs-Stage3 |
1.421020E-01 |
| Stage2-vs-Stage4 |
1.972140E-02 |
| Stage3-vs-Stage4 |
2.526000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.37427871702312E-14 |
| Normal-vs-AfricanAmerican |
9.79140000190171E-08 |
| Normal-vs-Asian |
7.59630136570877E-11 |
| Caucasian-vs-AfricanAmerican |
6.152400E-01 |
| Caucasian-vs-Asian |
7.660000E-01 |
| AfricanAmerican-vs-Asian |
7.842400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.32986979603811E-15 |
| Normal-vs-Female |
1.64468438867971E-12 |
| Male-vs-Female |
8.910300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.72473146875518E-12 |
| Normal-vs-Age(41-60Yrs) |
1.86517468137026E-14 |
| Normal-vs-Age(61-80Yrs) |
1.68398628375144E-12 |
| Normal-vs-Age(81-100Yrs) |
1.088310E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.669700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.720000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.004200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.742400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.544000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.524980E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.265350E-01 |
| Classical-VS-Follicular |
6.494600E-01 |
| Classical-VS-Other |
3.459000E-01 |
| Classical-VS-Normal |
1.63724589441472E-12 |
| Tall-VS-Follicular |
3.795400E-01 |
| Tall-VS-Other |
8.857000E-01 |
| Tall-VS-Normal |
1.2208000166325E-09 |
| Follicular-VS-Other |
5.567200E-01 |
| Follicular-VS-Normal |
4.32449998033491E-09 |
| Other-VS-Normal |
1.600180E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.9960036108132E-15 |
| Normal-vs-N1 |
3.1641356201817E-12 |
| N0-vs-N1 |
3.821000E-01 |
|
|
